Adaptive Phage Therapeutics
Jonathan Leff is a Partner on the Biotherapeutics team at Deerfield and Chairman of the Deerfield Institute and joined the Firm in 2013. Mr. Leff focuses on venture capital and structured investments in biotechnology and pharmaceuticals. Prior to Deerfield, for more than 16 years, Mr. Leff was with Warburg Pincus, where he held the position of Managing Director from 2000 to 2012 and led the firm’s investment efforts in biotechnology and pharmaceuticals. Mr. Leff has also been active in public policy discussions related to healthcare and medical innovation. He previously served as a member of the Executive Committee of the Board of the National Venture Capital Association (NVCA) and led NVCA’s life sciences industry efforts as Chair of NVCA’s Medical Innovation and Competitiveness Coalition (NVCA-MedIC). He also served on the Emerging Companies Section Board of the Biotechnology Industry Organization. Mr. Leff is a Board member of several not-for-profit organizations, including the Spinal Muscular Atrophy Foundation, Friends of Cancer Research, Reagan-Udall Foundation, and the Columbia University Medical Center Board of Advisors. Mr. Leff received his A.B. from Harvard University and earned his MBA from the Stanford University Graduate School of Business.
This person is not in the org chart
This person is not in any offices
Adaptive Phage Therapeutics
Adaptive Phage Therapeutics (APT) is a clinical-stage company advancing therapies addressing multi-drug resistant infections. Prior antimicrobial therapeutic approaches have been “fixed,” while pathogens continue to evolve resistance to each of those therapeutics, causing those drug products to become rapidly less effective in commercial use as antimicrobial resistance (AMR) increases over time.